«APOMORPHINE» 관련 영어 책
다음 도서 목록 항목에서
apomorphine 의 용법을 확인하세요.
apomorphine 에 관련된 책과 해당 책의 짧은 발췌문을 통해 영어 서적에서 단어가 사용되는 맥락을 제공합니다.
1
Drug Discovery and Evaluation: Pharmacological Assays
Apomorphine HCl is injected s.c. at a dose of 1.5mg/kg. The animals are placed
in individual plastic cages. A 10s observation period is used to measure the
presence of stereotypic activity such as sniffing, licking and chewing 10min after ...
2
Principles of Treatment in Parkinson's Disease
Non-ergot Dopamine Agonists Apomorphine Apomorphine is a potent mixed D1-
and D2-type DA receptor agonist with powerful antiparkinsonian effects.
Bioavailability is poor when administered orally due to extensive first-pass
metabolism.
Anthony Henry Vernon Schapira, Charles Warren Olanow, 2005
3
Parkinson's Disease and Other Movement Disorders
Apomorphine is one of the oldest synthesized drugs still in general use. It was
discovered in 1869 when it was found that dehydration of morphine produced a
new compound. Apomorphine is a dopamine agonist that is solely used in an ...
Mark Edwards, Niall Quinn, Kailash Bhatia, 2008
4
Living with Parkinson's Disease
Early clinical trials confirmed that apomorphine has a potent, rapid, and
predictable antiparkinsonian effect. It was not used clinically because of its side
effects, especially vomiting, and because it could not be given by mouth. This
situation has ...
Kathleen E. Biziere, M.D., Ph.D. and Matthias C. Kurth, M.D., Ph.D.
5
Scientific Basis for the Treatment of Parkinson's Disease, ...
Apomorphine Apomorphine (Bertek Pharmaceuticals, Inc.) is a reduced form of
morphine that acts as a dopamine agonist with selectivity for D1 and D2
receptors. It appears to have low abuse potential, in part due to the side-effects (
e.g. ...
Nestor Galvez-Jimenez, 2013
6
The Pharmacology of Sleep
I. Dopamine2-Agonists In rats, apomorphine, a D2 agonist, reduced sleep at
doses causing stereo- typic behavior (kafi and Gaillard 1976). In dogs,
apomorphine produced a dose-related increase in wakefulness and a decrease
in SWS and ...
Anthony Kales, J. Adrien, 1995
7
Key Clinical Trials in Erectile Dysfunction
Nasal spray (n = 2) Apomorphine (1.25 mg/puff) Sublingual tablet (n = 8)
Apomorphine (2.5 and 5 mg) Sublingual liquid (n = 12) Apomorphine (10 and 20
mg) Sublingual controller Apomorphine (3 and 4 mg) release (CR) tablet (n = 12)
...
8
Handbook of Parkinson's Disease, Fourth Edition
Apomorphine The Food and Drug Administration (FDA) approved apomorphine,
a nonergoline dopamine agonist, as a subcutaneously injected treatment for
severe off episodes in 2004. It was first used in the 1930s as an emetic and was ...
Rajesh Pahwa, Kelly E. Lyons, 2013
9
Standard Practice in Sexual Medicine
The history of apomorphine dates back to 1869 when its first synthesis from
morphine was reported by Mathiessen [1 5] . The dopaminergic activities of
apomorphine were first published in the mid 19605 when it was successfully
administered ...
Hartmut Porst, Jacques Buvat, 2008
10
Basal Ganglia Diseases—Advances in Research and Treatment: ...
The following quote was obtained by the news editors from the background
information supplied by the inventors: “This application relates to liquid
pharmaceutical compositions for the intranasal administration of apomorphine. “
Apomorphine ...
«APOMORPHINE» 단어를 포함하는 뉴스 기사
다음 뉴스 기사의 맥락에서 국내 및 국제 언론이 말하는 내용 및
apomorphine 단어를 사용하는 방법을 알아보세요.
UPDATED: Cynapsus' sublingual Parkinson's med for 'off' episodes …
Cynapsus ($CYNA) kicked off patient enrollment in its Phase III clinical trial of sublingual apomorphine for Parkinson's patients who suffer from ... «FierceDrugDelivery, 6월 15»
Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 …
Apomorphine is the most potent and fast-acting of all the dopamine agonists, which are used to stimulate dopamine receptors in place of ... «SYS-CON Media, 6월 15»
Cynapsus Therapeutics (CYNA) Announces Enrollment of First …
"We believe that the combination of Apomorphine as the only approved drug to rapidly treat OFF episodes and our sublingual film delivery ... «StreetInsider.com, 6월 15»
Sublingual Apomorphine Improves Symptoms of Parkinson's …
APL-130277 is a sublingual apomorphine thin film under development for the on-demand treatment of “off” episodes associated with PD. «P&T Community, 6월 15»
NeuroDerm Ltd. Short Interest Update
The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinsons disease. author-avatar ... «The Daily Rover, 6월 15»
Why Making Dramatic Moves: Cynapsus Therapeutics (NASDAQ …
Cynapsus Therapeutics (NASDAQ:CYNA) announced data from clinical trials of APL-130277, a sublingual apomorphine thin film under ... «Stock Transcript, 6월 15»
Cynapsus Therapeutics' APL-130277 Improved Parkinson's …
Efficacy of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's disease; Hauser et al. «FierceDrugDelivery, 6월 15»
Injected Apomorphine Rapidly Treats Morning Akinesia in Parkinson's
SAN DIEGO — For patients with Parkinson's disease, subcutaneous injections of apomorphine work more rapidly than oral levodopa for ... «Neurology Advisor, 6월 15»
Acorda's inhaled levodopa shows promise in Phase II trials
In addition, Cynapsus is developing a noninjectable version of second-line Parkinson's med apomorphine. - read the release. Related Articles: «FierceDrugDelivery, 6월 15»
Zacks Short Term Rating on NeuroDerm Ltd. (NASDAQ:NDRM)
The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinsons disease. 5 Veggies ... «American Trade Journal, 6월 15»
